Published in World J Hepatol on June 08, 2015
Infectious Complications After Liver Transplantation. Gastroenterol Hepatol (N Y) (2015) 0.76
Chronic hepatitis B: update 2009. Hepatology (2009) 16.08
EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol (2008) 9.14
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int (2012) 4.52
Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med (1993) 4.43
Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34
HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology (2008) 2.84
Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology (2009) 2.35
Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology (2010) 2.32
Failure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B. J Hepatol (2005) 2.19
Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology (1998) 2.19
Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation (1996) 2.09
Revisiting the natural history of chronic hepatitis B: impact of new concepts on clinical management. J Gastroenterol Hepatol (2007) 2.00
Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology (2011) 1.89
Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology (2015) 1.87
Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet (1996) 1.78
Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther (2007) 1.76
Oral nucleoside/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B. Am J Gastroenterol (2013) 1.73
Presence of intrahepatic (total and ccc) HBV DNA is not predictive of HBV recurrence after liver transplantation. Liver Transpl (2007) 1.64
Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. Hepatology (2003) 1.59
Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. Hepatology (2002) 1.58
Identification of hepatitis B virus-specific lymphocytes in human liver grafts from HBV-immune donors. Liver Transpl (2007) 1.58
Lamivudine or lamivudine combined with hepatitis B immunoglobulin in prophylaxis of hepatitis B recurrence after liver transplantation: a meta-analysis. Transpl Int (2008) 1.57
Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol (1992) 1.46
HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis. Hepatology (2003) 1.44
No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology (2014) 1.43
A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology (2001) 1.29
A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology (2008) 1.27
Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. Hepatology (2000) 1.24
Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology (1996) 1.17
High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. J Hepatol (1999) 1.17
Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment. J Gastroenterol Hepatol (2014) 1.12
Hepatitis B virus DNA in liver, serum, and peripheral blood mononuclear cells after the clearance of serum hepatitis B virus surface antigen. J Med Virol (2004) 1.11
Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin. Hepatology (1998) 1.05
Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl (2000) 1.04
Evidence for selection of hepatitis B mutants after liver transplantation through peripheral blood mononuclear cell infection. J Hepatol (1997) 0.99
Prevention of recurrent hepatitis B virus infection after liver transplantation: hepatitis B immunoglobulin, antiviral drugs, or both? Systematic review and meta-analysis. Transpl Infect Dis (2009) 0.96
Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation. Liver Transpl (2013) 0.96
Hepatitis B immunoglobulin and Lamivudine improve hepatitis B-related outcomes after liver transplantation: meta-analysis. Clin Gastroenterol Hepatol (2008) 0.94
Ablation of persistent hepatitis B by bone marrow transplantation from a hepatitis B-immune donor. Gastroenterology (1993) 0.94
Hepatitis B virus immunization with an adjuvant containing vaccine after liver transplantation for hepatitis B-related disease: failure of humoral and cellular immune response. Transpl Int (2006) 0.90
New paradigms for the treatment of chronic hepatitis B. J Gastroenterol Hepatol (2008) 0.89
Hepatitis B virus infection in lymphatic tissues in inactive hepatitis B carriers. J Hepatol (2005) 0.89
Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis. Ann Surg (2001) 0.89
New therapeutic targets and drugs for the treatment of chronic hepatitis B. Semin Liver Dis (2013) 0.87
Significance of hepatitis B virus core-related antigen and covalently closed circular DNA levels as markers of hepatitis B virus re-infection after liver transplantation. J Gastroenterol Hepatol (2013) 0.87
Efficacy of a pre-S containing vaccine in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B. Am J Transplant (2007) 0.85
Successful hepatitis B vaccination in patients who underwent transplantation for hepatitis B virus-related cirrhosis: preliminary results. Liver Transpl (2002) 0.82
Is hepatitis B immunoglobulin necessary in prophylaxis of hepatitis B recurrence after liver transplantation? A meta-analysis. PLoS One (2014) 0.81
HBV vaccination in liver transplant recipients: not an effective strategy in the prophylaxis of HBV recurrence. J Viral Hepat (2005) 0.80
Hepatitis B virus replication within the human spleen. J Clin Microbiol (1990) 0.80
Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay. Hepatol Int (2012) 0.79
Sanctuary of hepatitis B virus in bone-marrow cells of patients undergoing liver transplantation. Liver Transpl Surg (1996) 0.77
Hepatitis B immune globulin dose requirements following orthotopic liver transplantation for chronic hepatitis B cirrhosis. Transplant Proc (1996) 0.76
Era of direct acting antivirals in chronic hepatitis C: Who will benefit? World J Hepatol (2015) 0.76